EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
| Formula | C25H28N6O |
| Net Charge | 0 |
| Average Mass | 428.540 |
| Monoisotopic Mass | 428.23246 |
| SMILES | CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nnnn2)cc1 |
| InChI | InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30) |
| InChIKey | YOSHYTLCDANDAN-UHFFFAOYSA-N |
| Wikipedia |
|---|
| Roles Classification |
|---|
| Chemical Roles: | environmental contaminant Any minor or unwanted substance introduced into the environment that can have undesired effects. Bronsted base A molecular entity capable of accepting a hydron from a donor (Brønsted acid). Bronsted acid A molecular entity capable of donating a hydron to an acceptor (Brønsted base). |
| Biological Roles: | angiotensin receptor antagonist A hormone antagonist that blocks angiotensin receptors. antiviral agent A substance that destroys or inhibits replication of viruses. xenobiotic A xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means. |
| Applications: | angiotensin receptor antagonist A hormone antagonist that blocks angiotensin receptors. hypoglycemic agent A drug which lowers the blood glucose level. anti-arrhythmia drug A drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres. cardiovascular drug A drug that affects the rate or intensity of cardiac contraction, blood vessel diameter or blood volume. renoprotective agent Any compound that is able to prevent damage to the kidneys. antihypertensive agent Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| irbesartan (CHEBI:5959) has role angiotensin receptor antagonist (CHEBI:61016) |
| irbesartan (CHEBI:5959) has role anti-arrhythmia drug (CHEBI:38070) |
| irbesartan (CHEBI:5959) has role antihypertensive agent (CHEBI:35674) |
| irbesartan (CHEBI:5959) has role antiviral agent (CHEBI:22587) |
| irbesartan (CHEBI:5959) has role cardiovascular drug (CHEBI:35554) |
| irbesartan (CHEBI:5959) has role environmental contaminant (CHEBI:78298) |
| irbesartan (CHEBI:5959) has role hypoglycemic agent (CHEBI:35526) |
| irbesartan (CHEBI:5959) has role renoprotective agent (CHEBI:231911) |
| irbesartan (CHEBI:5959) has role xenobiotic (CHEBI:35703) |
| irbesartan (CHEBI:5959) is a azaspiro compound (CHEBI:35624) |
| irbesartan (CHEBI:5959) is a biphenylyltetrazole (CHEBI:48420) |
| irbesartan (CHEBI:5959) is a organic molecular entity (CHEBI:50860) |
| irbesartan (CHEBI:5959) is a α-amino acid (CHEBI:33704) |
| IUPAC Name |
|---|
| 2-butyl-3-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one |
| INN | Source |
|---|---|
| irbesartan | ChemIDplus |
| Synonyms | Source |
|---|---|
| 2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one | IUPAC |
| BMS 186295 | ChemIDplus |
| BMS-186295 | ChEMBL |
| Irbesartan | KEGG COMPOUND |
| Irbesartan bms | ChEMBL |
| Irbesartan teva | ChEMBL |
| Brand Names | Source |
|---|---|
| Avapro | KEGG DRUG |
| Irbesartan component of avalide | ChEMBL |
| Irbesartan component of coaprovel | ChEMBL |
| Irbesartan component of ibersartan/hydrochlorothiazide ibersartan | ChEMBL |
| Irbesartan component of ibersartan/hydrochlorothiazide teva ibersartan | ChEMBL |
| Irbesartan component of ibersartan/hydrochlorothiazide zentiva ibersartan | ChEMBL |
| Registry Numbers | Sources |
|---|---|
| Reaxys:6620400 | Reaxys |
| CAS:138402-11-6 | ChemIDplus |
| CAS:138402-11-6 | KEGG COMPOUND |
| Citations |
|---|